OC 8721 WANECAM II – A CLINICAL TRIAL PROGRAMME TO ASSESS SAFETY, EFFICACY AND TRANSMISSION-BLOCKING PROPERTIES OF A NEW ANTIMALARIAL KAF156 (GANAPLACIDE) IN UNCOMPLICATED MALARIA IN WEST AND CENTRAL AFRICA
Djimde A, Grobusch M, Zoleko Manego R, Mombo-Ngoma G, Picot S, Sagara I, Sutherland C, Kone A, Doumbo O, Pedro Gil J, Björkman A, Borrmann S, Soulama I, Fofana B, Duparc S, Dicko A, Hughes D, Winnips C, Sirima S, Adehossi E, Ouedraogo J, Dembele L, Zongo I, Biguenet S, Ilboudo-Sanogo E, Fofana A. OC 8721 WANECAM II – A CLINICAL TRIAL PROGRAMME TO ASSESS SAFETY, EFFICACY AND TRANSMISSION-BLOCKING PROPERTIES OF A NEW ANTIMALARIAL KAF156 (GANAPLACIDE) IN UNCOMPLICATED MALARIA IN WEST AND CENTRAL AFRICA. BMJ Global Health 2019, 4: a17.3-a18. DOI: 10.1136/bmjgh-2019-edc.43.Peer-Reviewed Original ResearchTrial programNew antimalarial drug combinationMajor public health problemAntimalarial drug combinationsClinical trial programPublic health problemYears of ageNew antimalarial drugsClinical research teamRegulatory health authoritiesNew antimalarial treatmentsUncomplicated malariaFalciparum malariaAntimalarial treatmentPatient adherenceCombination therapySingle dosesClinical trialsClinical studiesKAF156Drug combinationsArtemisinin derivativesClinical developmentDrug development pipelineHealth problems